Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells
Authors:
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 448, 61-69
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Krebshilfe, Germany (111298)
This publication has 26 references indexed in Scilit:
- Giant cell tumor of bone: updated molecular pathogenesis and tumor biologyHuman Pathology, 2018
- Mechanism of cancer: Oncohistones in actionJournal of Genetics and Genomics, 2018
- Every amino acid matters: essential contributions of histone variants to mammalian development and diseaseNature Reviews Genetics, 2014
- Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of boneNature Genetics, 2013
- Giant Cell Tumor of BoneJournal of the American Academy of Orthopaedic Surgeons, 2013
- DAXX-dependent supply of soluble (H3.3–H4) dimers to PML bodies pending deposition into chromatinGenome Research, 2012
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomaNature, 2012
- Histone onco-modificationsOncogene, 2011
- Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic RegionsCell, 2010
- Local Recurrence of Giant Cell Tumor of Bone After Intralesional Treatment with and without Adjuvant TherapyJournal of Bone and Joint Surgery, 2008